Schizophrenia: Attitudes of Patients and Professional Carers Towards the Illness and Antipsychotic Medication

 

 Buy Article Permissions and Reprints

Background: Non-compliance with antipsychotic medication is known to be one of the major reasons for relapse in patients with schizophrenia. Carers might be able to reduce noncompliance by enhancing the patient’s knowledge about the illness and antipsychotic medication and by carrying out regular benefit/risk discussions concerning the treatment plan, thereby improving the patient’s attitudes towards pharmacological treatment. Methods: In this cross-sectional study we used a semistructured interview to investigate the attitudes towards the illness and antipsychotic medication of patients with schizophrenia and of medical and non-medical professionals involved in their treatment. An array of 24 outpatients with schizophrenia, 21 psychiatrists, 26 nurses and 42 non-medical health professionals were investigated. Results: We found compliance in 54.2 %, partial compliance in 8.3 % and non-compliance in 37.5 % of patients. More patients than carers judged other disorders like epilepsy and diabetes to be worse than schizophrenia. Patients stated more often, that they would not encourage a relative to take antipsychotic medication. An extent of 71.4 % of psychiatrists and 35 % of non-medical professionals reported a general willingness to take antipsychotic medication themselves, if they were to suffer from schizophrenia. Conclusions: Our results indicate that the attitude of carers is not only different from patients but also remarkably heterogeneous within the group of carers. This needs to be taken into account when planning compliance-enhancing measures.

References

• 1 Adams S G, Howe J T. Predicting medication compliance in a psychotic population.  J Nerv Ment Dis. 1993;  181 558-560
  PubMedGoogle Scholar
• 2 Angermeyer MC, Daumer R. Benefits and risks of psychotropic medication in the eyes of the general public: results of a survey in the Federal Republic of Germany.  Pharmacopsychiatry. 1993;  26 114-120
  PubMedGoogle Scholar
• 3 Barnas C, Hummer M, Fleischhacker W W. Compliance problems in treatment of schizophrenic patients.  Wien Med Wochenschr. 1998;  148 281-283
  PubMedGoogle Scholar
• 4 Becker M H, Maimann L A. Sociobehavioural determinants of compliance with health and medical care recommendations.  Med Care. 1975;  13 10-24
  PubMedGoogle Scholar
• 5 Blackwell B. Treatment adherence.  Br J Psychiat. 1976;  129 513-531
  PubMedGoogle Scholar
• 6 Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia.  Psychol Med. 1992;  22 787-797
  PubMedGoogle Scholar
• 7 Burns T, Guest L. Running an assertive community treatment team.  Adv Psychiat Treatment. 1999;  5 348-356
  PubMedGoogle Scholar
• 8 Fleischhacker W W, Meise U, Günther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects.  Acta Psychiat Scand. 1994;  89 (suppl. 382) 11-15
  PubMedGoogle Scholar
• 9 Gaebel W, Pietzker A. One year outcome of schizophrenic patients-the interaction of chronicity and neuroleptic treatment.  Pharmacopsychiatry. 1985;  18 235-239
  PubMedGoogle Scholar
• 10 Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker W W. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia.  J Clin Psychiat. 2002;  63 49-53
  PubMedGoogle Scholar
• 11 Hogan TP: Awad A G, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.  Psychol Med. 1983;  13 177-183
  PubMedGoogle Scholar
• 12 Holzinger A, Löffler W, Muller P, Priebe S, Angermeyer M C. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.  J Nerv Ment Dis. 2002;  190 597-603
  CrossrefPubMedGoogle Scholar
• 13 Jorms A F. Belief about the helpfulness of interventions for mental disorders: a comparison of general practitioners, psychiatrists and clinical psychologists.  Aust NZ J Psychiat. 1997;  31 844-851
  PubMedGoogle Scholar
• 14 Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia.  Acta Psychiat Scand. 1994;  89 (Suppl. 382) 16-24
  PubMedGoogle Scholar
• 15 Ley P, Spelman M S. Communication in an outpatient setting.  Br J Soc Clin Psychol. 1965;  4 114-116
  PubMedGoogle Scholar
• 16 Lima J, Nazarian L, Charney E, Lahti C. Compliance with short term antimicrobial therapy. Some techniques that help.  Pediatrics. 1976;  57 383-386
  PubMedGoogle Scholar
• 17 Linden M. Therapeutische Ansätze zur Verbesserung von Compliance.  Nervenarzt. 1979;  50 109-114
  PubMedGoogle Scholar
• 18 Ludwig W, Huber D, Schmidt S, Bender W, Greil W. Assessment of Compliance related attitudes in psychiatry.  Soc Psych Psych Epid. 1990;  25 298-303
  PubMedGoogle Scholar
• 19 McCabe R, Quayle E, Beirne A D, Anne Duane M M. Insight, global neuropsychological functioning, and symptomatology in chronic schizophrenia.  J Nerv Ment Dis. 2002;  190 519-525
  CrossrefPubMedGoogle Scholar
• 20 Meise U, Günther V, Gritsch S. Die Bedeutung der Arzt-Patienten-Beziehung für die Patientencompliance.  Wien Klin Wochenschr. 1992;  104 267-271
  PubMedGoogle Scholar
• 21 Millar E, Garland C, Ross F, Kendrick T, Burns T. Practice nurses and the care of patients receiving depot neuroleptic treatment: views on training, confidence and use of structured assessment.  J Adv Nurs. 1999;  29 1454-1461
  CrossrefPubMedGoogle Scholar
• 22 Motlova L. Psychoeducation as an indispensable complement to pharmacotherapy in schizophrenia.  Pharmacopsychiatry. 2000;  33 (Suppl. 1) 47-48
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Oehl M, Hummer M, Fleischhacker W W. Compliance with antipsychotic treatment.  Acta Psychiat Scand. 2000;  102 (Suppl. 407) 83-86
  PubMedGoogle Scholar
• 24 Rettenbacher M A, Hofer A, Eder-Ischia U, Hummer M, Kemmler G, Weiss E, Fleischhacker W W. Compliance in Schizophrenia: psychopathology, side effects and patients` attitudes towards the illness and medication. J Clin Psychiat 2004 in press
  Google Scholar
• 25 Stein L I, Test M A. Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation.  Arch Gen Psychiat. 1980;  37 392-397
  PubMedGoogle Scholar
• 26 Weiden P, Papkin B, Mott T, Zygmunt A, Goldman D, Horwitz-Lennon M, Frances A. Rating of medication influences (ROMI) scale in schizophrenia.  Schizophr Bull. 1994;  20 297-310
  PubMedGoogle Scholar
• 27 Wright E C. Non-compliance - or how many aunts has Mathilda?.  Lancet. 1993;  342 909-913
  CrossrefPubMedGoogle Scholar

Maria A. Rettenbacher

Dept. of Biological Psychiatry

Innsbruck University Clinics

Anichstrasse 35

6020 Innsbruck

Austria

Phone: +43-512-504-3636

Fax: +43-512-504-3628

Email: maria.rettenbacher@uibk.ac.at